Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,545 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic Clear all
Completed Phase 2 Interventional Results available

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

NCT01677377
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Little Rock, Alaska • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

NCT05306275
View directory record Official record
Conditions
Healthy Participants
Interventions
CSL312
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00000865
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 13 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Capravirine to Treat Children With HIV Infection

NCT00006519
View directory record Official record
Conditions
HIV Infection
Interventions
Capravirine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2006 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

NCT06045507
View directory record Official record
Conditions
HIV, HIV Pre-exposure Prophylaxis
Interventions
MK-8527, Placebo to MK-8527
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
North Hollywood, California • San Francisco, California • Hallandale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

NCT06190678
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Anaheim, California • Edgewater, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 2, 2026, 7:17 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

NCT06014658
View directory record Official record
Conditions
Cancer
Interventions
Antibody-Drug Conjugate
Drug
Lead sponsor
MBrace Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 2, 2026, 7:17 AM EDT
Terminated Phase 1 Interventional

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

NCT01286974
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
[14C]linifanib, ABT-869, linifanib
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 2, 2026, 7:17 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

NCT06782659
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001, Viagra, ASP-001
Drug · Device
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors

NCT00949559
View directory record Official record
Conditions
Solid Tumors, Advanced Solid Tumors
Interventions
EP-100
Drug
Lead sponsor
Esperance Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

NCT01259479
View directory record Official record
Conditions
Solid Tumors, Brain Tumors, Brain Metastases
Interventions
Satraplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

NCT01916135
View directory record Official record
Conditions
Carcinoma, Sarcoma, Myeloma, Lymphoma, Melanoma
Interventions
[18F]-SKI-249380, PET/CT scan, Blood draws
Radiation · Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

NCT02697240
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Intravenous citrulline
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
6 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 2, 2026, 7:17 AM EDT
Recruiting Phase 2 Interventional

Motivation for IV Alcohol Self-Administration in Humans

NCT06494891
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous Alcohol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 2, 2026, 7:17 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers

NCT02205320
View directory record Official record
Conditions
Pharmacokinetics
Interventions
DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B
Biological
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

NCT01563562
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Bardoxolone Methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

NCT00295061
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Alpha-1 MP, alpha-1 proteinase inhibitor (human)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

NCT01904773
View directory record Official record
Conditions
Tourette Syndrome
Interventions
AZD5213 and placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

NCT01700270
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
dovitinib (TKI258), fluvoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
View directory record Official record
Conditions
HIV/AIDS, Contraception
Interventions
tenofovir/emtricitabine, DMPA
Combination Product · Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

NCT02430870
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TAK-648, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Anaheim, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 2, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

NCT03785366
View directory record Official record
Conditions
Women at Risk for Pregnancy
Interventions
VeraCept, ParaGard
Drug
Lead sponsor
Sebela Women's Health Inc.
Industry
Eligibility
Up to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 2, 2026, 7:17 AM EDT